Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome
Suchira Gallage,Elaine E Irvine,Jose Efren Barragan Avila,Virinder Reen,Silvia M A Pedroni,Imanol Duran,Vikas Ranvir,Sanjay Khadayate,Joaquim Pombo,Sharon Brookes,Danijela Heide,Gopuraja Dharmalingham,Agharul I Choudhury,Indrabahadur Singh,Nicolás Herranz,Santiago Vernia,Mathias Heikenwalder,Jesús Gil,Dominic J Withers
DOI: https://doi.org/10.1038/s43587-024-00695-z
2024-08-29
Abstract:Inhibition of S6 kinase 1 (S6K1) extends lifespan and improves healthspan in mice, but the underlying mechanisms are unclear. Cellular senescence is a stable growth arrest accompanied by an inflammatory senescence-associated secretory phenotype (SASP). Cellular senescence and SASP-mediated chronic inflammation contribute to age-related pathology, but the specific role of S6K1 has not been determined. Here we show that S6K1 deletion does not reduce senescence but ameliorates inflammation in aged mouse livers. Using human and mouse models of senescence, we demonstrate that reduced inflammation is a liver-intrinsic effect associated with S6K deletion. Specifically, we show that S6K1 deletion results in reduced IRF3 activation; impaired production of cytokines, such as IL1β; and reduced immune infiltration. Using either liver-specific or myeloid-specific S6K knockout mice, we also demonstrate that reduced immune infiltration and clearance of senescent cells is a hepatocyte-intrinsic phenomenon. Overall, deletion of S6K reduces inflammation in the liver, suggesting that suppression of the inflammatory SASP by loss of S6K could underlie the beneficial effects of inhibiting this pathway on healthspan and lifespan.